- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Product Innovation & Availability
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
April 8, 2019
Earlier this year, the US Government’s National Institutes of Health (NIH) Division of AIDS (DAIDS) published its Funding Opportunity Announcement (FOA), signaling its priorities for the 2021-2027 funding cycle for HIV research. The US public sector is the largest global funder of HIV prevention research and the announcement has major implications for shaping the landscape of HIV research globally. Outlined in the FOA, DAIDS is looking to fund research that will advance antibodies, vaccines, multi-purpose technologies (MPTs) and antiretrovirals (ARVs) as prevention, as well as research on social and behavioral strategies, among other things.
In this episode of Px Pulse, hear DAIDS leader Carl Dieffenbach and colleague, Director Sheryl Zwerski address the position of non-systemic strategies of prevention at the January AIDS Research Advisory Committee meeting, where the priorities of the FOA were presented. (Non-systemic strategies such as topical microbicides do not provide protection throughout the body.) A major leader in HIV prevention science, South African researcher Linda-Gail Bekker talks about an ideal future pipeline, a research agenda she calls the “science of choice”. And AVAC’s Manju Chatani-Gada talks to two young women advocates from Zimbabwe who explain the limits of prevention today and why more choices will mean greater empowerment.
Maximina Jokonya is a mentor for Africaid and Audrey Nosenga works for Zimbabwe Young Positives.
Listen to the full podcast (24:01).
Highlights
- DAIDS’ position on non-systemic prevention products (2:34)
- Linda Gail Bekker on the pros and cons of the current HIV prevention strategies (5:38)
- Linda Gail Bekkers’ “science of choice” (2:03)
- Linda Gail Bekker on the future research pipeline (2:10)
- Linda Gail Bekker makes the case for non-systemic products (3:17)
- Young women advocates on the short reach of prevention today and how to improve it (6:29)
Additional Resources
Graphics
- The Future of ARV-Based Prevention and More
- Vaccine Efficacy Trials Pipeline
- HIV-Specific Neutralizing Antibodies — Targets and research status
Reports
- Whose Choice is it Anyway? – International Rectal Microbicide Advocates (IRMA)
- Develop Long-Term Solutions to End the Epidemic: No Shortcuts - AVAC
- AVAC Report 2018: No Choice, No Prevention Part 2 - AVAC